Dr Sadaf Ali MRCP

Dr Sadaf Ali

Institute of Metabolism and Systems Research
Clinical Research Fellow

Contact details

Email
sxa1566@student.bham.ac.uk
Twitter
@Sadaf39414690
Address
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Sadaf Ali is a Clinical Research Fellow currently pursuing a PhD at the Institute of Metabolism and Systems Research, funded by University Hospitals Birmingham. Her research is centred on unravelling the mechanisms underlying insulin resistance in obesity and type 2 diabetes, with a focus on utilizing Alström syndrome, a rare monogenic disorder, as a model for cardio-metabolic disease. Her project delves into investigating the dysfunction of adipose tissue and skeletal muscle as key contributors to insulin resistance.

Sadaf received her primary medical qualification in 2011 from Khyber Medical University, Peshawar, Pakistan before moving to UK. She completed her Core Medical Training and initial years of Higher Specialist Training in Diabetes & Endocrinology in the Northwest Region before relocating to Birmingham in 2021 to embark on her PhD journey.

In recognition of her academic prowess and dedication to medical research, Sadaf has been appointed as an NIHR Academic Clinical Lecturer in Diabetes and Endocrinology, with her tenure set to commence in August 2024. This prestigious appointment underscores her commitment to advancing knowledge in the field of diabetes and endocrinology while bridging the gap between academia and clinical practice.

Qualifications

  • Membership of the Royal College of Physicians, 2016
  • M.B.B.S., Khyber Medical University, Pakistan, 2011

Other activities

  • Committee member for SfE National Obesity Database Steering group
  • Member of Society of Endocrinology (SfE)
  • Member of Endocrine Society
  • Member of Diabetes UK(DUK)
  • Specialist Registrar in Diabetes Endocrinology, University Hospitals Birmingham NHS Foundation Trust

Publications

Zhang Q, Ali S, Anwunai I,Xavier G , Dawson C ,Dassie F, Tang Y, Wang L, Chang G, Warfield A, Paisey R, Barrett T, Maffei P,Wang X, Kershaw M, and Geberhiwot T(2024), Defining puberty and spectrum of hypogonadism in Alström Syndromic.JCEM [Epub ahead of print]

Ali S, Baig S, Wanninayake S, da Silva Xavier G, Dawson C, Paisey R, Geberhiwot T. Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients. Diabetes Obes Metab. 2024 Mar;26(3):989-996. doi: 10.1111/dom.15398. Epub 2023 Dec 27. PMID: 38151964.

Baig S, Wanninayake S, Foggensteiner L, Elhassan YS, Manolopoulos K, Ali S, Lassen PB, Clément K, Steeds RP, Tomlinson JW, Geberhiwot T. Adipose tissue function and insulin sensitivity in syndromic obesity of Bardet-Biedl syndrome. Int J Obes (Lond). 2023 May;47(5):382-390. doi: 10.1038/s41366-023-01280-x. Epub 2023 Feb 20. PMID: 36807608.

Bashir B, Haslam S, Ahmad S, Elnaggar MN, Allcock R, Ali S, Kyi NM, Salazar L, Gbegbaje A, Banerjee M. Protein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies (PCSK9mab) in Clinical Practice at Secondary Care - Real World Multicentre Experience. Cureus. 2022 Dec

Ali S, Mathew S, Pappachan JM. Acute cor pulmonale from saddle pulmonary embolism in a patient with previous COVID-19: should we prolong prophylactic anticoagulation? Int J Infect Dis. 2020 Aug;97:299-302. doi: 10.1016/j.ijid.2020.06.039. Epub 2020 Jun 13. PMID: 32544670; PMCID: PMC7293501.

Ali S, Ali O, Ahmed I, Nazir T. Trifascicular Block and Ventricular Standstill: A Late Complication of Mediastinal Radiotherapy in a Cancer Survivor. Cureus. 2021 Jan 20;13(1):e12806. doi: 10.7759/cureus.12806. PMID: 33628674; PMCID: PMC7894380. 

Harshal D, Deepa N, Maria P, Sadaf A ,Thozhukat S.PCSK9 inhibitors in familial hypercholesterolemia-a real world experience and meta-analysis, British Journal of Cardiology,2019